These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Therapeutic face of RNAi: in vivo challenges. Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911 [TBL] [Abstract][Full Text] [Related]
5. Critical issues in delivery of RNAi therapeutics in vivo. Rivera S; Yuan F Curr Pharm Biotechnol; 2012 Jun; 13(7):1279-91. PubMed ID: 22201583 [TBL] [Abstract][Full Text] [Related]
6. Targeted delivery systems of small interfering RNA by systemic administration. Kawakami S; Hashida M Drug Metab Pharmacokinet; 2007 Jun; 22(3):142-51. PubMed ID: 17603214 [TBL] [Abstract][Full Text] [Related]
7. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Guzman-Aranguez A; Loma P; Pintor J Br J Pharmacol; 2013 Oct; 170(4):730-47. PubMed ID: 23937539 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620 [TBL] [Abstract][Full Text] [Related]
11. Focus on RNA interference: from nanoformulations to in vivo delivery. Karp JM; Peer D Nanotechnology; 2018 Jan; 29(1):010201. PubMed ID: 29185433 [No Abstract] [Full Text] [Related]
12. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. DeVincenzo JP Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462 [TBL] [Abstract][Full Text] [Related]
13. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery. Singh SK; Hajeri PB Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929 [TBL] [Abstract][Full Text] [Related]
14. Efficient delivery of HBV NLS siRNAs into HepG2.2.15 cells for HBV inhibition through novel recombinant preS1‑tP proteins. Zeng Y; Li Z; Shang J; Kang Y Int J Mol Med; 2018 Aug; 42(2):1181-1189. PubMed ID: 29786106 [TBL] [Abstract][Full Text] [Related]
15. In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation. Hegde V; Hickerson RP; Nainamalai S; Campbell PA; Smith FJ; McLean WH; Pedrioli DM J Control Release; 2014 Dec; 196():355-62. PubMed ID: 25449884 [TBL] [Abstract][Full Text] [Related]
16. RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics. Snead NM; Rossi JJ Nucleic Acid Ther; 2012 Jun; 22(3):139-46. PubMed ID: 22703279 [TBL] [Abstract][Full Text] [Related]
17. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274 [TBL] [Abstract][Full Text] [Related]
18. RNA interference inhibitors of hepatitis B virus. McCaffrey AP Ann N Y Acad Sci; 2009 Sep; 1175():15-23. PubMed ID: 19796073 [TBL] [Abstract][Full Text] [Related]
19. Specific anti-viral effects of RNA interference on replication and expression of hepatitis B virus in mice. Wu Y; Huang AL; Tang N; Zhang BQ; Lu NF Chin Med J (Engl); 2005 Aug; 118(16):1351-6. PubMed ID: 16157029 [TBL] [Abstract][Full Text] [Related]
20. [Advance in research of anti-HBV and anti-HCV through RNAi]. Cai DC; Ren H Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):126-8. PubMed ID: 14980131 [No Abstract] [Full Text] [Related] [Next] [New Search]